Expired activity
Please go to the PowerPak homepage and select a course.

Optimizing Asparaginase Therapy for Acute Lymphoblastic Leukemia:
Oncology Pharmacist and Nurse Perspectives

Jointly Provided by Postgraduate Healthcare Education, LLC (PHE) and Postgraduate Institute for Medicine (PIM).

This activity is supported by an independent educational grant from Jazz Pharmaceuticals.

PowerUpLive Session Date and Time

Thursday, November 17, 2022
3:00 – 3:30 PM ET

Faculty

Ryan J. Daley, PharmD, BCOP
Clinical Pharmacy Specialist, Leukemia
Memorial Sloan Kettering Cancer Center
New York, NY

Katherine L. Byar, MSN, ANP, BC, BMTCN
Nurse Practitioner, Hematologic Malignancy
Nebraska Medicine
Fred & Pamela Buffett Cancer Center
Omaha, NE

FINANCIAL DISCLOSURE

Dr. Daley has disclosed that he has received consulting fees for Da Volterra (Paris, France) and has an ownership interest (less than 5%) in Aprea Therapeutics, Inc.

Ms. Byar has disclosed that she has no relevant affiliations or financial relationships with a commercial interest to disclose.

Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

The PIM planners and others have nothing to disclose.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

ACCREDITATION STATEMENTS

acpePHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0430-9999-22-068-L01-P
Credits: 0.5 hour (0.05 ceu)

Joint Accreditation statement
Joinly Accredited Provider

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 30 minutes

TARGET AUDIENCE

This accredited activity has been designed for Oncology Pharmacists, Nurses & Nurse Practitioners

HOW TO EARN CREDIT: PHARMACISTS

Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live event; and 3) complete the evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.

HOW TO EARN CREDIT (NURSES)

  • Navigate to www.cmeuniversity.com
  • Login or Create a New Account (will take less than 1 minute)
    • If you receive a message when creating a new account that “the email you entered is already in use”, please click the Forgot my Username or Password link to have your Username and Password sent to you via email, you may have previously participated in an activity hosted by CME University
    • After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
  • Type in 17137 at the top of the page, "Find Post-Test/Evaluation by Course"
  • Click on the activity title when it appears
  • Choose the type of credit you desire
  • Complete the online Evaluation
  • Receive an immediate CE Certificate to download and/or print for your files

If you have questions about ANCC credit, please contact PIM at inquiries@pimed.com.

GOAL

The goal of this PowerUp Recap Live Q&A session is to provide learners who completed the case-based monograph titled, Optimizing Asparaginase Therapy for Acute Lymphoblastic Leukemia: Oncology Pharmacist and Nurse Perspectives, the opportunity to ask the faculty questions about the use of asparaginase for the treatment of acute lymphoblastic leukemia including types of approved agents, efficacy, toxicity, and approaches for adverse event prevention and management. Participation is limited.

EDUCATIONAL OBJECTIVES

Upon completion of this program, participants should be better able to:

  • Recognize the differences among available forms of asparaginase and patient-specific factors to consider when selecting a type of asparaginase to treat patients with ALL
  • Discuss approaches to identify, mitigate and manage toxicities associated with the use of asparaginase for the treatment of ALL

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine (PIM), or Jazz Pharmaceuticals. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA.